IE43130B1 - Improvements in throat pastilles - Google Patents

Abstract

1476057 Throat pastilles UNICLIFFE Ltd 17 March 1976 [20 March 1975] 11601/75 Heading A5B [Also in Division C3] Throat pastilles contain a base formulation comprising (a) potato starch which has been cross-linked by propylene oxide and epichlorohydrin and (b) amylopectin which has been treated with α-amylase and then esterified with vinyl acetate, the ratio of (a):(b) being 1:2 to 1:4 by weight. Other ingredients include glucose, sugar, citric acid, glycerin, an antiseptic, flavouring, colouring, agents and purified water. The antiseptic may be T.C.P. (Trade Mark).

Description

Thia invention relates to base formulations for throat pastilles, and to throat pastilles derived therefrom, Guin acacia is generally used as the base formulation in conventional throat pastilles, but in recent times it lias become very expensive.

A need therefore exists for a low cost base formulation which has similar properties to gum acacia and which is suitable for human consumption.

Thus, according to the present invention there is provided a starch-derived base formulation for a throat pastille comprising (a) potato starch which has been cross-linked by propylene oxide and epichlorohydrin and (b) amylopectin which has been treated with (/-amylase and then cstorified with vinyl acetate, the ratio of (a)i(b) by weight being from 1:2 to 1:4.

According tc a further aspect of the invention there is provided L5 a throat pastille having a starch-derived base formulation as defined above The throat pastilles of the invention have been found to be very acceptable to the consumer when sucked in the mouth, and generally have little tendency to fragment, i.e. to break up into smaller pieces, on . sucking.

A suitable cross-linked starch for component (a) is Liconal11 (Trade Mark), a product commercially available from Royal Scholten-Honig (Trading) Limited of Whitefield, Manchester.

A suitable modified amylopectin for component (b) is Amylogum CL 400S (Trade Mark), a product commercially available from Tunnel Avebe Starches Limited, of Gillingham, Kent. The amylopectin for Amylogum CL 400S is obtained by separation from potato starch.

The ratio of component (a) to component (b) referred to above is critical to the production of an acceptable base formulation and throat pastille. We have found that larger quantities of Amylogum result ) in a throat pastille which is inflexible and tends to fragment when sucked in the mouth, and larger quantities of Liconal produce a pastille having anunpleasantly sticky texture. More preferably, theratio of (a):(b) is from 1:2.5 to 1:3.5 by weight, and is most preferably about 1:3 by weight. - 2 43130 Throat pastilles may be prepared from the base formulation of the invention by conventional methods.

A typical formulation for a sugar-coated lemon-flavoured throat pastille according to the pre! sent invention xs as follows :- Base formulation) of the invention) 15 - 40% by weLght of the finished sugar-coated pastille Liquid glucose 15 - 4o% hy H of It It II tl II Sugar (including i5 - 40% hy It of ti It H It II coating) Citric Acid 0.1 - 1.1% by 11 of 11 It II 11 II Yellow colouring / Trace amount Liquid antiseptic about 10% by II of 11 It II u u Lemon oil about 1% by II of It tl II II 11 Glycerin about 1% by ll of tl η II II II Purified water Balance to 100% by It of it 11 It If it Preferably the purified water is present ir 1 an amount of no more than % by weight.

Such a pastille may be prepared by mixing.an aqueous solution of the cross-linked starch of (a) with ah aqueous solution of the modified amylopectin of (b), followed by heating the resulting solution to boiling. The weight ratio of (a) to (b) must of course be from 1:2 to 1:4. When the solution is boiling, the appropriate amounts of sugar and liquid glucose are added, and the solution boiled until concentrated e.g. to approximately 74% by weight solids, as determined/by a refractometer.

The resulting formulation is then strained, and allowed to cool. When the solution has cooled to about 80°C, a mixture of the colouring agent, liquid antiseptic, lemon oil, citric acid ar.d glycerin may be added with stirring. The mixture is then allowed to cool further to about 55°C, and deposited into starch pastille moulds. After drying to · form say, an 80-95% hy weight solids content, the pastilles are separated from the moulds, dusted, steamed and then coated with a small amount of /to 16% sugar, typically in an amount of about 6 by weight of the finished sugarcoated pastille. Sugar-coating is of course optional but does result in the production of a more acceptable pastille. - 3 4 313 0 As stated above, the base formulation is generally present in an amount of from 15-40% by weight of the finished pastille, the preferred quantity being from 30-35%· The most preferred sugar-coated lemonflavoured pastille formulation of the invention does, in fact, have the following composition:- Araylogum CL 400S 24% by weight of the finished sugar-coated pastille Liconal 8% by tl of tl tt It It tt Liquid glucose 18% by It of It It It II (In pastille 18% by tt of ti tl tt tt tlSu9ar(Coating 15% by It of tl It It 1» It . ) Citric Acid 1.0% by tt of tt II it II tt F.D. & C. Yellow No. 5 0.03% by tr of tt II tt It tt TCP Liquid 10% by tt of It II tt tt 11 Antiseptic ' lemon oil 0.8% by tt of II It II tl It Glycerin 1.0% by 11 of tt II tt It tl Purified water about 4.17% by It of tt II tt tl 1 TCP is a Trade Mark.

Of course, alternative flavouring agents, colourants, antiseptics and additives to those mentioned above may be added to the pastille base formulation of the invention as will be known to those skilled in the art. For example, a preferred sugar-coated blackcurrantflavoured pastille of the invention has the following formulation:- Amylogum CL 400S 24% by weight of the finished sugar- coated pastille Liconal 8% by II of If tt II II II Liquid glucose 18% by II of tt It It II 11 (In pastille 18% by It of tt tt It tt It Sugar (Coating 14% by It of It » tl It tt Citric Acid 0.9% by tl of It If II II II Phosphoric Acid 0.27% by II of. tl It tt tt It TCP Liquid Antiseptic 10% by It of tt It tt tt tt Glycerin 1.0% by tt of It 11 It It F.D. & C.Dlue No.2 0.019% by 11 of it I! tl II t: F.D. & C.Yellow No5 0.003% by II of It II It It tl -4.4 313 0 F.D. & C. Red No. 2 0.011% Florasynth (Trade Mark) L 6603 Blackcurrant flavouring 1.0% Purified water about 4.8% The following Examples by weight of the finished pastille by of ” by of illustrate the invention:EXAMPLE 1 Amylogum CL 400S (24 gms) was dissolved in purified water (72 ml) with the aid of a high speed mixer. ’’Licanal” (8 gms) was dissolved in purified water (24 ml), also with the aid of a high speed mixer, and both solutions were placed in a steam-jacketed copper pan. The resulting mixture was heated to boiling, with stirring, and liquid glucose (glucose/water) (18 gms) and sugar (18 gms) were added. The solution was then boiled at about 116°C until concentrated to a solids content of approximately 74% by weight, as determined by a refractaneter.

The formulation was then strained through a 16 mesh sieve, and transferred to a cooling vessel. When the solution had cooled to about 8O°C, a solution containing F.D. & C Yellow No. 5 colouring (0.013 gms), TCP (Trade Mark) liquid antiseptic (11.6 gms), 2u lemon oil (0.8 gms), glycerin (1.0 gms) and citric acid (0.227 gms) was added. The solution was then mixed, allowed to de-aerate, and the solids content measured and found to be approximately 65% by weight. The solution was allowed to cool to 55°C, and was then deposited in a nwtoer of pastille sized starch moulds. After drying to a water content of about 12% by weight, the pastilles were separated from the moulds, dusted, steamed and coated with a small amount of sugar.

(The total amount of sugar used to coat the pastilles was 6 gms.) The antiseptic throat pastilles produced were of excellent texture and flexibility and had a lemon flavour. - 5 43130 EXAMPLES 2 TO 5 The procedure of Example 1 was repeated, but using different amounts of Amylogum CI, 400S and Liconal: - Example Noe Amount of Amylogum CL 400S used (grns) Amount of Liconal used (gms) 2 21.4 10.6 ,? 23 9 'it25 7 10 5 25.6 6.4 The antiseptic pastilles all had an excellent lemon flavour. Those of Examples 3 and 4 were of good texture and flexibility and those of Examples 2 and 5» acceptable.

EXAMPLE 6 The process of Example 1 was repeated with the exception that, when the Antylogum/Uconal/liquid glucose/sugar solution had cooled to about 80°C, a solutioh containing citric acid (0.9 gms), phosphoric acid (0.26 gms), TCP” (Trade Mark) liquid antiseptic (11.6 gms), glycerin (l gm), F.D. & C. Blue No. 2 (0.019 gms), F.D. & C„ Yellow No. 5 (0.003 gms), F.D. & C. Red No. 2 (O.Oll gms) and Florasynth L 6603 blackcurrant flavouring (1.0 gms) was added in place of the Yellow No. 5/T.C.P./lemon oil/glycerino/citric acid solution of Example 1.

The pastilles produced were of excellent texture and flexibility and had a blackcurrant flavour.

EXAMPLES 7 TO 10 The process of Example 6 was repeated using the following amounts of Liconal and Amylogum:- 6 43130 Example No. Amount of Amylogum CL 400S used (gms) Amount of Liconal used ( gms) 7 21.4 10.6 5 8 23 9 9 25 7 10 25.6 6.4 The pastilles all had an excellent blackcurrant flavour and were of good or acceptable flexibility and texture.

EXAMPLE 11 The process of Example 1 was repeated except that (a) the amounts of citric acid, F.D. and C. Yellow Ko. 5 ar.d TCP liquid antiseptic used were, respectively, 1.03, 0.037 and 10.2 gms., (b) the pastilles were dried to a water content of about 5% by weight and (c) the total amount of sugar used to coat the pastilles was 15 gms.

EXAMPLE IS The process of Example 6 was repeated except that (a) the amount of phosphoric acid and TCP liquid antiseptic used were respectively 0.27 and 10*1 gm3·, (b) the pastilles were dried to a water content of about 5% by weight, and (c) the total amount of sugar used to coat the pastilles was l4 gms.

Claims (14)

1. A starch-derived base formulation for a throat pastille comprising: (a) potato starch which has been cross-linked by propylene oxide and epichlorohydrin and (b) amylopectin which has been treated with «-aitiylase and then esterified with vinyl acetate, the ratio of (a): (b) by weight being from 1:2 to 1:4.

2. A base formulation as claimed in claim 1 wherein the ratio of (a) to (b) is from 1:2.5 to 1:3.5 by weight.

3. A base formulation as claimed in claim 2 wherein the ratio is about 1:3 by weight.

4. A throat pastille having a base formulation as claimed in any one of claims I to 3.

5. A throat pastille as claimed in claim 4 wherein the base formulation comprises 15 - 40¾ by weight of the pastille.

6. A throat pastille as claimed in claim 5 wherein the base formulation comprises 30 - 35% by weight of the pastille.

7. A throat pastille as claimed in any one of claims 4 to 6 which includes glucose, sugar, citric acid, glycerin, an antiseptic, flavouring and colouring agents, and purified water.

8. A throat pastille as claimed in claim 7 wherein the water comprises no more than 15% by weight of the pastille.

9. A throat pastille as claimed in claim 4 substantially as hereinbefore described in any one of Examples 1 to 10.

10. A throat pastille as claimed in claim 4 substantially as hereinbefore described in Example

11. Or 12. - 8 43130

12. A process for preparing a throat pastille as claimed in claim 4, which comprises mixing an aqueous solution of component (a) with an aqueous solution of component (b), the weight ratio of component (a) to component (b) being from li2 to 1;4, heating the 5 resulting solution to boiling, adding the desired emounts of sugar and liquid glucose, boiling the resulting solution until it is concentrated to a solids content of approximately 7 ! i% by weight, «training, cooling to about 80°C, adding with stirring the antiseptic, 'citric acid, glycerin and flavouring and colouring agents, cooling to 10 about 55°θ, depositing the mixture into starch pastillo moulds, drying the resulting pastilles to a solids content of 80 - 95% by weight, separating the pastilles from the moulds, dusting, steaming, and finally optionally coating tho finished pastille with a small amount of sugar. 15 12. Λ process as claimed in claim 11 substantially as hereinbefore described in any one of Examples 1 to 10.

13. Λ process as claimed in claim 11 substantially as hereinbefore described in Example 11 or 12.

14. A pastille as claimed in claim 7 which has been prepared by a 20 process as claimed in any one of claims 11 to 13.